GWPH News and Press, GW Pharmaceuticals Plc From 06/27/19

Research into the therapeutic benefits of cannabis is prompting a paradigm shift in many sectors of the healthcare industry. What about medical cannabinoids in pediatric care? When she was just seven months old in June 2013, Sophie Ryan ’s parents learned their daughter had an inoper...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 27, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) today announced that Adrian Rawcliffe, currently Chief Financial Officer (CFO) of the Company, will succeed James Noble as Chief Executive Officer (CEO). This tran...

Introduction Zogenix ( ZGNX ) is developing low-dose fenfluramine, ZX008, for the treatment of pediatric epileptic syndromes (e.g. Dravet and Lennox-Gastaut). My original investment thesis in Zogenix was based upon the following beliefs: The efficacy of ZX008 supports use as standar...

Listen on the go! Subscribe to The Cannabis Investing Podcast on Libsyn , Spotify , Stitcher or Apple Podcasts . By Rena Sherbill Today, I am very happy to be joined by Martin Tindall, CEO and Director of Phoenix Life Sciences (PLSI). Martin ha...

Following a rough end to 2018 and a strong start to 2019, GW Pharmaceuticals plc ( GWPH , GWPRF ) is now trading in a fairly tight range. The second half of 2019 could see the European approval of the company's drug Epidiolex, an event discussed in this article, which might send the stock to ...

CannabisNewsWire Editorial Coverage : The cannabis sector continues its steady shift toward big business and big money, with much of growth based on acquisitions, agreements and consistent research. TransCanna Holdings Inc. (CSE: TCAN) (FRA: TH8) ( TCAN Profile ) is focused on creating a ...

Zynerba ( ZYNE ) may be on to something with its transdermal CBD patch Zygel. The medication, if approved, could supplant GW Pharmaceuticals’ ( GWPH ) Epidiolex in the market. Zynerba has jumped 17% since news was released of its new patent on Zygel for the treatment of autism spectru...

The marijuana/cannabis sector is attracting a lot of investors due to its promises of future growth. Therefore, the critical question here is how to profit in this sector. In my view, this is a particularly tricky issue because it's still a nascent industry. It's incredibly challenging to dist...

Biotech Pulse Biotech shares are up this year, as represented by the Nasdaq Biotechnology Index ( IBB ), which is the industry benchmark, and the S&P Select Biotechnology Index ( XBI ), after a sharp decline in 2018. This is a welcome respite for biotech investors. However, it has not ...

Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc...